Literature DB >> 30840911

Navigating Two Roads to Glucose Normalization in Diabetes: Automated Insulin Delivery Devices and Cell Therapy.

Esther Latres1, Daniel A Finan1, Julia L Greenstein1, Aaron Kowalski1, Timothy J Kieffer2.   

Abstract

Incredible strides have been made since the discovery of insulin almost 100 years ago. Insulin formulations have improved dramatically, glucose levels can be measured continuously, and recently first-generation biomechanical "artificial pancreas" systems have been approved by regulators around the globe. However, still only a small fraction of patients with diabetes achieve glycemic goals. Replacement of insulin-producing cells via transplantation shows significant promise, but is limited in application due to supply constraints (cadaver-based) and the need for chronic immunosuppression. Over the past decade, significant progress has been made to address these barriers to widespread implementation of a cell therapy. Can glucose levels in people with diabetes be normalized with artificial pancreas systems or via cell replacement approaches? Here we review the road ahead, including the challenges and opportunities of both approaches.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  artificial pancreas; automated insulin delivery; continuous glucose monitoring; encapsulation; immunosuppression; stem cells; type 1 diabetes

Mesh:

Substances:

Year:  2019        PMID: 30840911     DOI: 10.1016/j.cmet.2019.02.007

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  26 in total

Review 1.  Engineering islets from stem cells for advanced therapies of diabetes.

Authors:  Johanna Siehler; Anna Karolina Blöchinger; Matthias Meier; Heiko Lickert
Journal:  Nat Rev Drug Discov       Date:  2021-08-10       Impact factor: 84.694

2.  Far-red light-activated human islet-like designer cells enable sustained fine-tuned secretion of insulin for glucose control.

Authors:  Guiling Yu; Mingliang Zhang; Ling Gao; Yang Zhou; Longliang Qiao; Jianli Yin; Yiwen Wang; Jian Zhou; Haifeng Ye
Journal:  Mol Ther       Date:  2021-09-14       Impact factor: 11.454

Review 3.  Liver to Pancreas Transdifferentiation.

Authors:  Irit Meivar-Levy; Sarah Ferber
Journal:  Curr Diab Rep       Date:  2019-08-02       Impact factor: 4.810

Review 4.  Economics of Beta-Cell Replacement Therapy.

Authors:  Cátia Bandeiras; Albert J Hwa; Joaquim M S Cabral; Frederico Castelo Ferreira; Stan N Finkelstein; Robert A Gabbay
Journal:  Curr Diab Rep       Date:  2019-08-02       Impact factor: 4.810

5.  Engineering Mammalian Cells to Control Glucose Homeostasis.

Authors:  Jiawei Shao; Xinyuan Qiu; Mingqi Xie
Journal:  Methods Mol Biol       Date:  2021

6.  Generation of insulin-producing pancreatic β cells from multiple human stem cell lines.

Authors:  Nathaniel J Hogrebe; Kristina G Maxwell; Punn Augsornworawat; Jeffrey R Millman
Journal:  Nat Protoc       Date:  2021-08-04       Impact factor: 13.491

Review 7.  Type 1 diabetes mellitus: much progress, many opportunities.

Authors:  Alvin C Powers
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

8.  A nanofibrous encapsulation device for safe delivery of insulin-producing cells to treat type 1 diabetes.

Authors:  Xi Wang; Kristina G Maxwell; Kai Wang; Daniel T Bowers; James A Flanders; Wanjun Liu; Long-Hai Wang; Qingsheng Liu; Chengyang Liu; Ali Naji; Yong Wang; Bo Wang; Jing Chen; Alexander U Ernst; Juan M Melero-Martin; Jeffrey R Millman; Minglin Ma
Journal:  Sci Transl Med       Date:  2021-06-02       Impact factor: 17.956

9.  Highly Efficient Differentiation of Human Pluripotent Stem Cells into Pancreatic Progenitors Co-expressing PDX1 and NKX6.1.

Authors:  Bushra Memon; Essam M Abdelalim
Journal:  Methods Mol Biol       Date:  2022

Review 10.  Mesenchymal Stem Cell-Based Therapy for Diabetes Mellitus: Enhancement Strategies and Future Perspectives.

Authors:  Haisen Li; Hao Zhu; Ting Ge; Zhifeng Wang; Chao Zhang
Journal:  Stem Cell Rev Rep       Date:  2021-03-05       Impact factor: 5.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.